ALRN (Aileron Therapeutics) Earnings growth in current year

Official company branding of Aileron Therapeutics, Inc. (ALRN)

Aileron Therapeutics (ALRN) has shifted its strategic focus toward the treatment of orphan lung pathologies and the drug LAL-101. The annual EPS change reflects these trends, with the current metric standing at 76.00. The company is monetizing its peptide platform to protect tissues during chemotherapy. Financial stability is maintained through successful capital raising, which ensures consistent funding for ongoing clinical research.

ALRN (Aileron Therapeutics Inc) Earnings growth in current year history from 07/04/2022 to 11/17/2026

Comprehensive metric breakdowns and analytics for aileronrx.com (ALRN)

Fundamental valuation:ALRN Aileron Therapeutics
Signature product of Aileron Therapeutics

The eps_yy_co metric measures the annual dynamics of net income per share, reflecting the efficiency of business capitalization through the percentage change in earnings. Investors utilize this metric to assess earnings growth rates and mitigate the risk of overpaying based on inflated expectations. By analyzing the relative EPS YoY trend, one can evaluate how investments in the development of healthy tissue protectants for chemotherapy translate into real financial results for Aileron Therapeutics (ALRN).

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Inc.) - Earnings growth in current year|Earnings growth in current year nuvalent.com|Earnings per share growth in current year Kymera (KYMR)|IDYA (IDEAYA Biosciences, Inc.) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics Inc)|Net earnings per share change in current year ORIC Pharma|Relay Therapeutics Inc - Earnings growth in current year|Earnings per share growth rate in current year Nurix Therapeutics, Inc.|TYRA (Tyra Biosciences, Inc.) - Net earnings per share growth this year|VSTM: Net earnings per one share growth for the current year|GLUE (monterosatx.com) - Earnings growth in current year|Earnings per share growth rate in current year Cullinan Therapeutics Inc CGEM|Earnings growth in current year IMRX|C4 Therapeutics - Earnings per share growth this year|Black Diamond Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year RPTX|PMVP: Net earnings per share growth this year|karyopharm.com - Net earnings per one share growth for the current year|PPCB: Earnings growth in current year|Bio Green Med Solution Inc - Earnings per share increase in current year|AADI (Aadi Bioscience Inc) - Earnings growth in current year|Earnings per share growth rate in current year blueprintmedicines.com BPMC|Earnings per share growth in current year GlycoMimetics Inc. (GLYC)|SWTX (SpringWorks) - Earnings per share increase in current year